ArticleCell2018
Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression.
RetractedErratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 112 papers.
0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 162 citations in OpenAlex.
- Immune regulation by erythroid cells: how erythroid progenitor cells and mature red blood cells shape immunity.Nature reviews. Immunology · 2026Review
- Terpenes as Potential Multi-Target Modulators of Chronic Stress-Induced Neuroendocrine-Immune Dysregulation.International journal of molecular sciences · 2026Review
- Elevated circulating bile acids driven erythrocyte osmotic resistance marks hepatobiliary disease.American journal of physiology. Gastrointestinal and liver physiology · 2026Article
- Metabolically and epigenetically reprogrammed splenic TRNP1Nature genetics · 2026Article
- Immune checkpoint B7x promotes immune evasion and resistance to PD-1/PD-L1 blockade in bladder cancer.Genes & diseases · 2026Article
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Enlarged splenic volume predicts poor survival and is associated with inflammatory imbalance in patients with diffuse large B-cell lymphoma.Blood research · 2026Article
- Multi-omics approaches reveal erythroid progenitor cell in cancer: from passive bystander to active player.Oncogene · 2026Review
- CD71BMC nephrology · 2026Article
- Tumor-derived DNA drives cancer-associated anemia by promoting reticulocyte clearance.Signal transduction and targeted therapy · 2026Article
- Artemin Serves as a Novel Predictive Biomarker and Exerts a Protective Effect Against Preterm Birth.Journal of inflammation research · 2026Article
- Tumor-Induced Rewiring of Splenic Niches: from Immune Organ to Cancer Accomplice.International journal of biological sciences · 2026Review
- Review
- Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism.The Journal of clinical investigation · 2025Article
- Residual Genetic Material in Mature Red Blood Cells.International journal of molecular sciences · 2025Review
- Lymphoma accelerates T cell and tissue aging.Cancer cell · 2025Article
- ST2Clinical and translational allergy · 2025Article
- Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical Model.Journal of clinical and translational hepatology · 2025Article
- Erythroblasts Promote the Development of a Suppressive Lymphocyte Phenotype via Treg Induction and PD1 Upregulation on the Surfaces of B-Cells: A Study on the Subpopulation-Specific Features of Erythroblasts.Current issues in molecular biology · 2025Article
- Circulating Back to Blood: Erythrocyte Precursors Put the Brakes on Acute Lung Injury.American journal of respiratory cell and molecular biology · 2025Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Correction · 2021-03-04Error in Image ·
- Commented on byCell genesis.2018
- Commented on by
- Erratum issued
Authors and funding
21 authors at 5 institutions in 1 country.
Yanmei HanNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Qiuyan LiuNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Jin HouNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Yan GuNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Yi ZhangNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Zhubo ChenCAMS-Oxford Joint Center for Translational Immunology, Department of Immunology & Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China.
Jia FanLiver Cancer Institute, Zhongshan Hospital, Institutes of Biomedical Science, Fudan University, Shanghai 200032, China.
Weiping ZhouThird Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China.
Shuangjian QiuLiver Cancer Institute, Zhongshan Hospital, Institutes of Biomedical Science, Fudan University, Shanghai 200032, China.
Yonghong ZhangCAMS-Oxford Joint Center for Translational Immunology, Department of Immunology & Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China; Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Tao DongCAMS-Oxford Joint Center for Translational Immunology, Department of Immunology & Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China; Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Ning LiCAMS-Oxford Joint Center for Translational Immunology, Department of Immunology & Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China; Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zhengping JiangNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Ha ZhuNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Qian ZhangNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Yuanwu MaInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing 100021, China.
Lianfeng ZhangInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing 100021, China.
Qingqing WangInstitute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China.
Yizhi YuNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Nan LiNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China.
Xuetao CaoNational Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, China; CAMS-Oxford Joint Center for Translational Immunology, Department of Immunology & Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing 100005, China; School of Medicine, Nankai University, Tianjin 300071, China. Electronic address: caoxt@immunol.org.
Second Military Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSun Yat-sen University · CNCapital Medical University · CNZhejiang University · CN
Funding
Medical Research Council G0600520Medical Research Council G1001046Medical Research Council MC_UU_00008/11Medical Research Council MR/L018942/1
Abstract
Identifying tumor-induced leukocyte subsets and their derived circulating factors has been instrumental in understanding cancer as a systemic disease. Nevertheless, how primary tumor-induced non-leukocyte populations in distal organs contribute to systemic spread remains poorly defined. Here, we report one population of tumor-inducible, erythroblast-like cells (Ter-cells) deriving from megakaryocyte-erythroid progenitor cells with a unique Ter-119
Indexed as
Disease ProgressionAnimalsApoptosisCarcinoma, HepatocellularCell MovementCell ProliferationEpithelial-Mesenchymal TransitionErythroblastsGene Expression Regulation, NeoplasticGlial Cell Line-Derived Neurotrophic Factor ReceptorsHep G2 CellsHumansLeukocyte Common AntigensLeukocytesLiver NeoplasmsMiceARTN protein, humanArtn protein, mouseGfra3 protein, mouseGlial Cell Line-Derived Neurotrophic Factor ReceptorsLeukocyte Common AntigensNerve Tissue ProteinsPtprc protein, mouseTransforming Growth Factor betaartemincancer immunotherapyerythroblast-likehepatocellular carcinomaprognosis biomarkerTer-119Ter-cell
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.